Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Madrigal Pharmaceuticals (NASDAQ: MDGL) will participate in three investor conference fireside chats in late November and early December 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Madrigal Pharmaceuticals (NASDAQ: MDGL) will participate in three investor conference fireside chats in late November and early December 2025. Presentations and live webcasts are scheduled as follows: Jefferies Global Healthcare Conference in London on Nov 20, 2025 at 8:30 A.M. GMT (3:30 A.M. ET); Evercore Healthcare Conference on Dec 2, 2025 at 4:15 P.M. ET; and Piper Sandler Healthcare Conference on Dec 3, 2025 at 1:30 P.M. ET. All fireside chats will be webcast live and can be accessed via Madrigal’s Investor Relations Events page.
Details
News Market Reaction – MDGL
On Nov 17, the day this news came out, MDGL closed 4.57% above the previous close.
Data tracked by StockTitan Argus for the Nov 17 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:
Jefferies Global Healthcare Conference in London
Thursday, Nov. 20, 2025 at 8:30 A.M. GMT (3:30 A.M. ET)
The presentation will be webcast live and may be accessed here.
8th Annual Evercore Healthcare Conference
Tuesday, Dec. 2, 2025 at 4:15 P.M. ET
The presentation will be webcast live and may be accessed here.
Piper Sandler 37th Annual Healthcare Conference
Wednesday, Dec. 3, 2025 at 1:30 P.M. ET
The presentation will be webcast live and may be accessed here.
The fireside chats will be webcast live and can be accessed by visiting Madrigal’s Investor Relations Events page.
About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.